Dr. Sausville is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Baltimore, MD 21201Phone+1 410-328-7394Fax+1 410-328-6896
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
Brigham and Women's HospitalResidency, Internal Medicine, 1979 - 1982
Albert Einstein College of MedicineClass of 1979
Certifications & Licensure
MD State Medical License 1982 - 2023
DC State Medical License 1988 - 2016
VA State Medical License 1982 - 2004- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma Start of enrollment: 2000 Nov 01
- Flavopiridol in Treating Patients With Refractory Cancer Start of enrollment: 1997 Aug 01
- Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer Start of enrollment: 1999 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 288 citationsPaullones are potent inhibitors of glycogen synthase kinase‐3β and cyclin‐dependent kinase 5/p25Maryse Leost, Christiane Schultz, Andreas Link, Yong-Zhong Wu, Jacek Biernat
European Journal of Biochemistry. 2000-10-01 - 77 citationsTargeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized miceAlonso Heredia, Nhut Le, Ronald B. Gartenhaus, Edward A. Sausville, Sandra Medina-Moreno
Proceedings of the National Academy of Sciences of the United States of America. 2015-07-28 - 110 citationsComparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client pr...Victoria Smith, Edward A. Sausville, Richard F. Camalier, Heinz-Herbert Fiebig, Angelika M. Burger
Cancer Chemotherapy and Pharmacology. 2005-04-20
Grant Support
- Umgcc PAUL Calabresi Clinical Oncology Training ProgramNational Cancer Institute2008–2011
- Clinical Research Shared ServiceNational Cancer Institute2008–2010
- Clinical Trial: Treatment Of Melanoma With Wild-Type P53 And A 100b Using PentaNational Center For Research Resources2009
- Treatment Of Melanoma With Wild-Type P53 And Detectable S100B Using Pentamidine:National Cancer Institute2008–2009
- Clinical Trial: Phase I Study Of IV 17-AAG And Oral BAY 43-9006 In Patients WithNational Center For Research Resources2008
- 0629gcc: A Phase I, Open-Label, Multi-Center, Dose-Escalation Study To Assess SLNational Center For Research Resources2007
- 0458gcc: A Phase I Dose Escalation Study Of Intravenous 17-AAGNational Center For Research Resources2007
- Phase 1 Of Sorafenib PLUS 17AAG In Solid Tumor PatientsNational Center For Research Resources2006
- Immunotoxin Protocols Under The Medicine Branch: TargeteDivision Of Clinical Sciences - Nci2001
- Protein Kinase Antagonists: Preclinical And ClinicalDivision Of Clinical Sciences - Nci1999–2001
- Immunotoxin Protocols Under The Medicine Branch: Targeted Therapy Of Lymphoid NEDivision Of Clinical Sciences - Nci2000
- Immunotoxin Protocols Under The Medicine Branch: Targeted Therapy Of Lymphoid NEODivision Of Clinical Sciences - Nci1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
